Cytognomix Cytognomix is a biotechnology company developing software-based solutions and reagents for clinical genomics. | ![]() Codex DNA Codex DNA (formerly SGI-DNA) is a biology company that provides solutions for DNA, RNA, and protein synthesis. | ![]() Senti Biosciences Senti Biosciences (formerly known as Dynamics Special Purpose) leverages expertise in cell engineering and biological programming to build the future of gene and cell based therapies. | ![]() Avrobio Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. | ||
Founding Date | Founding Date 2009 | Founding Date 2021 | Founding Date 2013 | Founding Date 2016 | Founding Date N/A |
Type | Type Private | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations London, CA HQ | Locations Alameda, US HQ | Locations San Diego, US HQ | Locations South San Francisco, US HQ | Locations Cambridge, US HQ |
Employees | Employees 3 | Employees 212 | Employees 108 | Employees 916% decrease | Employees 8573% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 2.7 m | Valuation ($) 10.2 m | Valuation ($) 5.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $27.5m (FY, 2023) | Revenue (est.) $22k (FY, 2025) | Revenue (est.) N/A |
Net income | Net income N/A | Net income N/A | Net income ($47.7m) (FY, 2023) | Net income ($61.4m) (FY, 2025) | Net income ($74.2m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 25m | Total funding raised $ 53m | Total funding raised $ 85m |

Science is a biotech company that develops technologies for serious unmet medical needs.
View company
Codex DNA (formerly SGI-DNA) is a biology company that provides solutions for DNA, RNA, and protein synthesis.
View company
Senti Biosciences (formerly known as Dynamics Special Purpose) leverages expertise in cell engineering and biological programming to build the future of gene and cell based therapies.
View company
Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
View company